HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $27
HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $25 to $27.
Stocks · News reference
ORIC®Pharmaceuticals Initiates Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat In Combination With NUBEQA
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abirateroneEntered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals granted 125,400 non-qualified stock options and 20,550 restricted stock units to five new non-executive employees as inducement for employment. The grants were approved by the Compensation Committee and comply with Nasdaq Rule 5635(c)(4). The company continues development of its clinical-stage oncology candidates including rinzimetostat for prostate cancer and enozertinib for NSCLC.
ORIC Pharmaceuticals Q2 EPS $(0.38) Misses $(0.36) Estimate
ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.36) by 5.56 percent. This is a 19.15 percent increase over losses of $(0.47) per share
8-K filing — Oric Pharmaceuticals, Inc. (ORIC)
Filed: 2026-08-03 AccNo: 0001193125-26-330568 Size: 423 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits